Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
about
Specifications of a continual reassessment method design for phase I trials of combined drugs.Using the time-to-event continual reassessment method in the presence of partial ordersA phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumoursTumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerationsAntineoplastic effect of decoy oligonucleotide derived from MGMT enhancer.Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapyCooperative cluster formation, DNA bending and base-flipping by O6-alkylguanine-DNA alkyltransferase.Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase.A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancerLive and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotectionTherapeutic potential of drugs to modulate DNA repair in cancer.The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors.Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine.Chemotherapy in the management of advanced cutaneous malignant melanoma.Resistance to chemotherapy in cancer: a complex and integrated cellular response.Substitution of aminomethyl at the meta-position enhances the inactivation of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine.Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.DNA repair proteins as molecular targets for cancer therapeutics.O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatribTopologies of complexes containing O6-alkylguanine-DNA alkyltransferase and DNA.Targeting DNA repair and the cell cycle in glioblastoma.Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs.Current and future directions for Phase II trials in high-grade glioma.Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.Interactions of human O6-alkylguanine-DNA alkyltransferase (AGT) with short single-stranded DNAs.Interactions of human O(6)-alkylguanine-DNA alkyltransferase (AGT) with short double-stranded DNAsTumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Synthesis and Antitumor Activity Evaluation of a Novel Combi-nitrosourea Prodrug: BGCNU.Identification of the Structural Features of Guanine Derivatives as MGMT Inhibitors Using 3D-QSAR Modeling Combined with Molecular Docking.Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT).Mutations that probe the cooperative assembly of O⁶-alkylguanine-DNA alkyltransferase complexes.Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions.A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
P2860
Q30412231-E87B4EC7-FAD2-43EC-8C1E-27DCBF7FFB04Q30422422-64E004D5-5647-4652-A30A-ADF60D17AF3AQ33384102-7515060F-2F13-4F81-BDDD-DE405407FC92Q33396508-0C8E272F-81E7-42EF-B344-530EC4DBEEF7Q33595174-6847E125-C20E-4D5B-A12F-0536A2EEAE06Q34418437-9629868B-D875-4253-B50C-05717DBA4DC8Q34612054-A2915007-A849-48F6-BB64-014E43AEA79AQ35608666-A60C1A8D-C9AF-4012-842A-9293FFBDD3C9Q36012002-BB487A4E-8CC6-44DB-8AD7-043E6C8F3B08Q36280616-5B9FDB29-F9D1-414A-B590-42F61A21E7FCQ36510730-234B338E-2580-4998-99B6-FDCF14552E06Q36667516-74107917-9C45-4B9C-9F9D-EB86AF469FAEQ36812597-B8914F91-E316-43C1-80CC-8CBF6C034AE7Q36822443-8AE3A7ED-3369-4984-A159-C839957411BAQ36964700-AB8F02EB-C9B7-45E0-87A4-42D5844AB459Q37003288-3FCB66A4-290E-4BDE-8CA5-6EFF6EB6FFAAQ37007984-5D5FB5F4-5CCE-420A-A0B6-62DF94EC6213Q37079652-A5A86FC8-621E-4925-B467-66132F87BCCBQ37105014-0B2C8368-1A00-42E5-90F2-AE3C53725CA8Q37121130-6A73584A-A57F-420B-89AD-F735CECE78B5Q37122690-8DD4CAB5-2CB0-48A2-A43A-3590145C48B6Q37160598-DBFEDEF1-7E0A-4C0D-BEE2-6357AF1743F6Q37177925-686E2834-505E-472E-B523-4854D29D7A69Q37330168-9B5594E5-9B7C-41A5-A680-6F81D55980B0Q37960389-AC41C2B0-E7F1-4CA7-B61D-C429DF0FEE42Q38019607-59F4D859-D86E-42E6-8462-D6E1DAAB67C5Q38094808-C9C33AF1-1487-47A7-8784-97D0AF818A3AQ38225830-C82F729A-1EE9-4247-B007-2009831604D7Q38307161-E557A211-60A4-40B5-B550-AE74B172BB59Q38358343-8ADD746E-009B-473E-AC0A-ADFA773B7BACQ38730989-E4D6B8B4-3EF6-4A75-B818-E2055550D493Q40336092-04EE4EDA-E30B-4975-8140-D7FE42949C9FQ40680395-DD1F74D2-60D4-4FE0-BC59-94EC35847996Q41771536-C58C2F75-8F2F-4105-9BCC-BB38D1E1F147Q42661776-EBF2FCC3-AA99-4E6E-B3C5-EFBE17C76095Q43159277-7399711E-AE3E-43AF-B78B-5AA003F775C8Q48114950-4A691243-136C-4AA9-8E41-F6B902C551DCQ55370601-04122CF9-B23C-4416-A579-A4C945487D84Q57569610-219583B7-6D37-4EAC-9BED-60A0F43A3B9C
P2860
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Lomeguatrib, a potent inhibito ...... ts with advanced solid tumors.
@en
type
label
Lomeguatrib, a potent inhibito ...... ts with advanced solid tumors.
@en
prefLabel
Lomeguatrib, a potent inhibito ...... ts with advanced solid tumors.
@en
P2093
P1476
Lomeguatrib, a potent inhibito ...... ts with advanced solid tumors.
@en
P2093
Debra Jowle
Dorothy Donnelly
Gavin Halbert
Geoffrey P Margison
Helen McGrath
John Bridgewater
Lindsey Gumbrell
Malcolm Ranson
Mark R Middleton
R Stanley McElhinney
P304
P356
10.1158/1078-0432.CCR-05-2198
P407
P577
2006-03-01T00:00:00Z